Last $10.38 USD
Change Today -0.19 / -1.80%
Volume 756.3K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mihael H. Polymeropoulos M.D.

Founder, Chief Executive Officer, President and Director, Vanda Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 6 board members in 1 different organizations across 1 different industries.

See Board Relationships
54$2,520,234
As of Fiscal Year 2013

Background*

Mr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since May, 2003. Dr. Polymeropoulos has also been the Chief Financial Officer at Vanda Pharmaceuticals, Inc. since August 6, 2010 and served as its Principal Accounting Officer since August 6, 2010. He served as Vice President and Head of the Pharmacogenetics Department at Novartis Pharmaceuticals Corporation (Maryland). He served as the ...

Read Full Background

Corporate Headquarters*

2200 Pennsylvania Avenue NW
Washington, District Of Columbia 20037

United States

Phone: 202-734-3400
Fax: 202-296-1450

Board Members Memberships*

2003-Present
Founder, Chief Executive Officer, President and Director

Education*

Bachelor's Degree
University of Patras

Other Affiliations*

Annual Compensation*

Salary$515,000
Total Annual Compensation$515,000

Stock Options*

Restricted Stock Awards$579,500
All Other Compensation$22,061
Exercisable Options2,090,148
Exercisable Options Value$10,639,889
Unexercisable Options319,000
Unexercisable Options Value$1,348,478
Total Value of Options$11,988,366
Total Number of Options2,409,148

Total Compensation*

Total Annual Cash Compensation$891,124
Total Short Term Compensation$515,000
Other Long Term Compensation$601,561
Total Calculated Compensation$2,520,234
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $10.38 USD -0.19

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Christopher A. Viehbacher Chief Executive Officer, Director and Member of Strategy Committee
Sanofi
€3.0M
Masayo Tada Chief Executive Officer, President, Representative Director and Chairman of Risk Management Committee
Sumitomo Dainippon Pharma Co., Ltd.
--
Glenn A. Oclassen Sr.Chairman of the Board, Chief Executive Officer and President
Transcept Pharmaceuticals, Inc.
$560.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.